S. S. Tolmachev

S. S. Tolmachev

Auto-generated profile, based on publicly available information

S. S. Tolmachev

Petrov National Medical Research Center of Oncology

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2020 in Journal of High Energy Physics
Verified
Journal Article
Open access
PDF file
SGS Gribanov
S Gribanov
APA Popov
A Popov
RAR Akhmetshin
R Akhmetshin
AAA Amirkhanov
A Amirkhanov
AAA Anisenkov
A Anisenkov
YYYu. Yudin
Yu. Yudin
The cross section of the process e + e − → ηπ + π − is measured using the data collected with the CMD-3 detector at the VEPP-2000 collider in the center-of-mass energy range from 1.1 to 2.0 GeV. The decay mode η → γγ is used for η meson reconstruction in the data sample corresponding to an integrated luminosity of 78.3 pb −1. The energy dependence of the e + e − → ηπ + π − cross section is fitted within the framework of vector meson dominance in order to extract the Γ(ρ(1450) → e + e − ) $$ \mathcal{B} $$ B (ρ(1450) → ηπ + π − ) and the Γ(ρ(1700) → e + e − ) $$ \mathcal{B} $$ B (ρ(1700) → ηπ + π − ) products. Based on conservation of vector current, the analyzed data are used to test the relationship between the e + e − → ηπ + π − cross section and the spectral function in τ − → ηπ − π 0 ντ decay. The e + e − → ηπ + π − cross section obtained with the CMD-3 detector is in good agreement with the previous measurements.

30 March 2020 in Cancer Urology
Verified
Journal Article
Open access
PDF file
MBMariya Vladimirovna Berkut
Mariya Vladimirovna Berkut
AAA. S. Artemjeva
A. S. Artemjeva
SRS. A. Reva
S. A. Reva
STS. S. Tolmachev
S. S. Tolmachev
SPS. B. Petrov
S. B. Petrov
ANA. K. Nosov
A. K. Nosov
Tolsotogo St., Saint Petersburg 197022, RussiaBackground. Prostate cancer (PCa) of a high and very high risk is a potentially fatal disease that requires an active multimodal approach, including the use of neoadjuvant drug treatment. As option for this treatment is neoadjuvant chemohormonal therapy (NCHT) followed by radical prostatectomy (RPE). However, data on the oncological results of treatment of such patients are still limited and the role of neoadjuvant therapy in the treatment of high and very high-risk PCa remains not fully understood.Objective: to assess the oncological results of treatment patients with localized and locally advanced PCa of high and very high risk after NCHT. Materials and methods. This was a prospective randomized study: patients with PCa of high and very high-risk groups (prostate specific antigen levels (PSA) 20 ng/ml and/or Gleason score ³8 and/or clinical stage T2c) were treated with RPE only (group RPE; n = 35) or NCHT followed by RPE (NCHT/RPE group; n = 36). The neoadjuvant course included the intravenous administration of docetaxel once every 21 days (75 mg/m2 up to 6 cycles) and the antagonist of the gonadotropin releasing hormone degarelix according to the standard scheme (6 subcutaneous injections every 28 days). After a follow-up examination evaluating the result of the neoadjuvant regimen, patients underwent RPE with extanded lymphadenectomy.Results. A mean follow-up was 37.08 ± 20.46 months. A statistically significant reduction of prostate specific antigen 50 % post-chemohormonal therapy was observed in all 36 cases. Lower postoperative stage was noticed in 38.5 % in NCHT/RPE group compared with 2.7 % in RPE group. Similarly, positive surgical margin rate was higher in group without neoadjuvant therapy – 40 and 25 % (RPE group). Cancerspecific survival was 97.2 % in NCHT/RPE group and 87.56 % in the RP group (p = 0.037), cancer specific survival rate – 91.4 % and 97.2 % respectively (log-rank test p = 0.22). At the same time, no statistically significant differences were obtained in 3-year recurrence free survival between groups: 38.8 % in NCHT/RPE group versus 43.6 % in the RPE group (log-rank test p = 0.36).Conclusion. Conducting NCHT before RPE is a safe and effective strategy in patients with PCa of high and very high risk groups and could improve oncological results.

26 December 2022 in Urology Herald
Verified
Journal Article
Open access
PDF file
DPD. S. Plevako
D. S. Plevako
MKM. S. Knyazeva
M. S. Knyazeva
ESE. I. Sidina
E. I. Sidina
MBMariya Vladimirovna Berkut
Mariya Vladimirovna Berkut
SRS. A. Reva
S. A. Reva
Anastasia MalekAnastasia Malek
Anastasia Malek
Introduction. A combination of antiandrogen and cytostatic drugs was justified in the neoadjuvant therapy of patients with high-risk prostate cancer (HiRPCa) in some clinical trials. The effectiveness of such therapy in each individual case depends on the sensitivity of cancer cells to the applied drugs. It makes possible the development of the new technologies to personalize therapeutic approach. MicroRNAs (miRNAs) are a class of regulatory molecules whose expression is altered in PCa cells and can be associated with the sensitivity/resistance of cancer cells to specific cytostatics, for instance, taxanes.Objective. To identify the potential-marker miRNAs of PCa cells sensitivity to taxanes.Materials and methods. Samples of PCa tissue (n. 56) obtained from patients underwent neo-adjuvant therapy (antiandrogen and taxanes) and radical prostatectomy; PCa cell lines (PC-3, DU-145, LNCap). Total RNAs isolation was carried out using miRNeasy FFPE Kit, LRU-100-50; miRCURY LNA miRNA Focus PCR Panel, All-MIR kits were used for semi-quantitative analysis of potentially marker microRNA molecules using sequential reverse transcription and PCR.Results. The effect of taxanes on PCa cells is associated with up-regulation of miR-106b expression and down-regulation of miR-200c expression in both in vivo and in vitro conditions.Conclusion. MiR-106b and miR-200c miRNAs are involved in the response of PCa cells to taxanes, and therapeutic modification of these molecules in PCa cells may present a potential strategy to increase their sensitivity to taxane-containing therapy. Appropriate innovative technology may be in demand in the treatment of HiRPCa-patients.